HSD17B13 and metabolic dysfunction-associated steatotic liver disease: These contradictory results suggest comprehensive roles of HSD17B13 in the development of NAFLD that remain to be demonstrated; whether HSD17B13 is a target for the development of drugs against NAFLD remains unclear.